<DOC>
	<DOC>NCT01218958</DOC>
	<brief_summary>This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study conducted in subjects diagnosed with alcohol dependence as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV). Subjects were randomized (2:2:1:1) to receive intramuscular (IM) injections of Medisorb® naltrexone 190 mg, Medisorb naltrexone 380 mg, placebo for Medisorb naltrexone 190 mg, or placebo for Medisorb naltrexone 380 mg (VIVITROL®). Study drug was administered every 4 weeks for a total of 6 injections.</brief_summary>
	<brief_title>ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults</brief_title>
	<detailed_description>All subjects received standardized biopsychosocial support therapy (BRENDA Approach [Volpicelli, JR [2001]; Guilford Press: New York]) at each visit. Subjects who completed this study (ie, received 6 injections of study drug and completed all study visits) and continued to meet eligibility criteria were given the option to enroll in extension study ALK21-003EXT (NCT01218971). A second extension, Study ALK21-010 (NCT00156923), was conducted subsequent to ALK21-003EXT.</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Diagnosis of alcohol dependence based on Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSMIV) criteria Male or nonpregnant, nonlactating female Able to provide TimeLine FollowBack (TLFB) alcohol consumption information for 90day period before detoxification and/or screening At least 2 episodes of heavy alcohol drinking per week during the 30 days before detoxification and/or screening Negative urine toxicological screen for opiates on day of randomization Noncustodial, stable residence and phone plus 1 contact with verifiable address and phone Primary Evidence of hepatic failure including: ascites, prolonged prothrombin time (PT) (international normalized ratio [INR] ≥1.7), bilirubin &gt;10% above upper limit of normal (ULN) and/or esophageal variceal disease Active hepatitis and/or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) higher than 3xULN History of pancreatitis Major depression with suicidal ideation, psychosis, bipolar disorder, or psychiatric disorders that would compromise subject's ability to complete the study Current dependence (within past year) per DSMIV criteria to benzodiazepines, opioids or cocaine Use of benzodiazepines and/or Ambien® (zolpidem tartrate) within 7 days prior to first dose of study medication Greater than 7 days inpatient treatment for substance use disorders within 30 days of randomization Use of any opioids and/or methadone within 14 days of screening, or likely requiring opioid therapy during study period Use of oral naltrexone or disulfiram within 14 days of screening Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactidecoglycolide (PLG)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Alcoholism</keyword>
</DOC>